Provided by Tiger Trade Technology Pte. Ltd.

Tempest Therapeutics Inc.

0.9089
-0.0783-7.93%
Pre-market: 0.98440.0755+8.31%07:01 EDT
Volume:189.50K
Turnover:181.06K
Market Cap:15.03M
PE:-0.20
High:0.9900
Open:0.9850
Low:0.9088
Close:0.9872
52wk High:12.23
52wk Low:0.8401
Shares:16.54M
Float Shares:11.46M
Volume Ratio:1.05
T/O Rate:1.65%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.5617
EPS(LYR):-19.4955
ROE:-931.14%
ROA:-79.37%
PB:-13.79
PE(LYR):-0.05

Loading ...

Jakarta Offers Prizes for Waste Sorting on Anniversary Peak Night

Tempo
·
Jun 25

Tempest Therapeutics CEO Matthew Angel reports indirect purchase of 231,482 shares for $499,999.12

Reuters
·
Jun 24

Tempest Therapeutics shareholders approved Nasdaq Rule 5635 share issuances at special meeting

Reuters
·
Jun 23

Tempest Therapeutics director John D. Yee files initial beneficial ownership statement

Reuters
·
Jun 18

Tempest Therapeutics director William Drake Richey files initial beneficial ownership statement

Reuters
·
Jun 09

Tempest Therapeutics - Nicholas Maestas Resigns as CFO Effective June 5, 2026 - SEC Filing

THOMSON REUTERS
·
Jun 05

Tempest Therapeutics adds Drake Richey, John Yee to board

Reuters
·
Jun 05

Tempest Therapeutics Appoints Drake Richey and John Yee, Md, Mph to Board of Directors

THOMSON REUTERS
·
Jun 05

Tempest Therapeutics issues unregistered warrant for up to 2,344,828 shares in inducement deal

Reuters
·
Jun 02

Tempest Therapeutics director Simantov resigns from board

Reuters
·
May 30

Tempest Therapeutics announces exercise of 1,172,414 warrants at reduced $1.73 per share price

Reuters
·
May 29

Tempest Therapeutics gets Nasdaq notice for failing $2.5 million equity rule

Reuters
·
May 23

Tempest Therapeutics directors Brady, Raab, Pellizzari resign from board

Reuters
·
May 23

Tempest Risk Solutions Appoints David Näslund As CEO

Reuters
·
May 20

Tempest net loss widens 155% to $27.7 million in Q1 2026

Reuters
·
May 15

Tempest Therapeutics Q1 net loss widens on asset acquisition costs

Reuters
·
May 15

Tempest Therapeutics Q1 Operating Income USD -27.719 Million

THOMSON REUTERS
·
May 15

Press Release: Tempest Reports First Quarter 2026 Financial Results and Provides Business Update

Dow Jones
·
May 15

Tempest Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview

Reuters
·
May 08

Tempest says TPST-2003 dual-target CAR-T hits 100% complete response in Phase 1 trials

Reuters
·
May 06